AI Article Synopsis
- The study examines the prevalence and clinical features of pneumococcal coinfection in COVID-19 patients, finding a 2% occurrence among 18 patients.
- Most patients (88%) showed radiological changes upon admission, with 29% having elevated procalcitonin levels, and the mortality rate was recorded at 12%.
- The authors suggest starting antimicrobial treatment if there's a moderate to high suspicion of bacterial coinfection, but emphasize the importance of discontinuing antibiotics if not confirmed.
Article Abstract
Objective: Currently the prevalence of pneumococcal coinfection in patients with COVID-19 is unknown. In this work we present its clinical characteristics, evolution and treatment.
Methods: Retrospective data collection from August to October 2020 in two hospitals in the Murcia region.
Results: Eighteen patients had COVID-19 diagnosed by PCR and pneumococcal infection confirmed by antigenuria, which represented a prevalence of 2%. A total of 88% had radiological alterations upon admission (two patients had an X-ray within normality) and 29% had elevated procalcitonin. Mortality in our series was 12%.
Conclusions: It could be reasonable to consider the start of antimicrobial therapy in those cases in which there is a moderate or high suspicion of bacterial coinfection, being essential the early suspension of antibiotic treatment if it is not confirmed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638830 | PMC |
| http://dx.doi.org/10.37201/req/151.2020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!